These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 38326579

  • 1. Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes.
    Wagner P, Gass P, Pöschke P, Eckstein M, Gloßner L, Hartmann A, Beckmann MW, Fasching PA, Ruebner M, Emons J, Erber R.
    Virchows Arch; 2024 Jul; 485(1):63-74. PubMed ID: 38326579
    [Abstract] [Full Text] [Related]

  • 2. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, Pavese J, Matsangou M, Bhattacharya P, Ueno Y, Wang X, Shah MA.
    Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
    Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Türeci Ö.
    Jpn J Clin Oncol; 2019 Sep 01; 49(9):870-876. PubMed ID: 31087075
    [Abstract] [Full Text] [Related]

  • 4. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
    Matsusaka K, Ushiku T, Urabe M, Fukuyo M, Abe H, Ishikawa S, Seto Y, Aburatani H, Hamakubo T, Kaneda A, Fukayama M.
    Oncotarget; 2016 Sep 27; 7(39):64168-64181. PubMed ID: 27580354
    [Abstract] [Full Text] [Related]

  • 5. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
    Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA.
    Lancet; 2023 May 20; 401(10389):1655-1668. PubMed ID: 37068504
    [Abstract] [Full Text] [Related]

  • 6. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
    Ogawa H, Abe H, Yagi K, Seto Y, Ushiku T.
    Gastric Cancer; 2024 Jul 20; 27(4):802-810. PubMed ID: 38724721
    [Abstract] [Full Text] [Related]

  • 7. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
    Iwaya M, Hayashi H, Nakajima T, Matsuda K, Kinugawa Y, Tobe Y, Tateishi Y, Iwaya Y, Uehara T, Ota H.
    Histopathology; 2021 Aug 20; 79(2):227-237. PubMed ID: 33590909
    [Abstract] [Full Text] [Related]

  • 8. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
    Waters R, Sewastjanow-Silva M, Yamashita K, Abdelhakeem A, Iwata KK, Moran D, Elsouda D, Guerrero A, Pizzi M, Vicentini ER, Shanbhag N, Ta A, Chatterjee D, Ajani JA.
    JCO Precis Oncol; 2024 May 20; 8():e2300543. PubMed ID: 38781542
    [Abstract] [Full Text] [Related]

  • 9. Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy.
    Maeda K, Uehara T, Hosoda W, Kuraishi Y, Ota H.
    Pathol Res Pract; 2024 Oct 20; 262():155537. PubMed ID: 39178509
    [Abstract] [Full Text] [Related]

  • 10. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases.
    Coati I, Lotz G, Fanelli GN, Brignola S, Lanza C, Cappellesso R, Pellino A, Pucciarelli S, Spolverato G, Guzzardo V, Munari G, Zaninotto G, Scarpa M, Mastracci L, Farinati F, Realdon S, Pilati P, Lonardi S, Valeri N, Rugge M, Kiss A, Loupakis F, Fassan M.
    Br J Cancer; 2019 Jul 20; 121(3):257-263. PubMed ID: 31235864
    [Abstract] [Full Text] [Related]

  • 11. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.
    Int J Cancer; 2014 Nov 01; 135(9):2206-14. PubMed ID: 24710653
    [Abstract] [Full Text] [Related]

  • 12. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
    Ruba S, Doherty D, Stewart CJR.
    Pathology; 2020 Feb 01; 52(2):197-205. PubMed ID: 31870502
    [Abstract] [Full Text] [Related]

  • 13. Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients.
    Kim M, Kang BW, Park J, Baek JH, Kim JG.
    Pathol Res Pract; 2024 Nov 01; 263():155628. PubMed ID: 39368365
    [Abstract] [Full Text] [Related]

  • 14. Comprehensive immunohistochemical analysis of the gastrointestinal and Müllerian phenotypes of 139 ovarian mucinous cystadenomas.
    Halimi SA, Maeda D, Ushiku-Shinozaki A, Goto A, Oda K, Osuga Y, Fujii T, Ushiku T, Fukayama M.
    Hum Pathol; 2021 Mar 01; 109():21-30. PubMed ID: 33275953
    [Abstract] [Full Text] [Related]

  • 15. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
    Jasani B, Taniere P, Schildhaus HU, Blighe K, Parry S, Wilkinson D, Atkey N, Clare-Antony S, McCabe C, Quinn C, CLDN Study GroupSee the details of CLDN Study Group members in the acknowledgments., Dodson A.
    Lab Invest; 2024 Jan 01; 104(1):100284. PubMed ID: 37949357
    [Abstract] [Full Text] [Related]

  • 16. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
    Jia K, Chen Y, Sun Y, Hu Y, Jiao L, Ma J, Yuan J, Qi C, Li Y, Gong J, Gao J, Zhang X, Li J, Zhang C, Shen L.
    BMC Med; 2022 Jul 11; 20(1):223. PubMed ID: 35811317
    [Abstract] [Full Text] [Related]

  • 17. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
    Dai J, Zheng H, Jin J, Cheng Y, Xu H.
    Cancer Cytopathol; 2023 Jun 11; 131(6):365-372. PubMed ID: 36793190
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression.
    Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ, Kong SH, Park DJ, Oh DY, Lee HJ, Im SA, Yang HK, Lee HS.
    Oncologist; 2024 Sep 21. PubMed ID: 39306800
    [Abstract] [Full Text] [Related]

  • 19. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, Yuan L, Ma Y.
    BMC Gastroenterol; 2023 Aug 16; 23(1):283. PubMed ID: 37582713
    [Abstract] [Full Text] [Related]

  • 20. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
    Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, Luchini C, Pietrantonio F, Ugolini C, Vanoli A, Fassan M.
    Pathol Res Pract; 2024 Feb 16; 254():155145. PubMed ID: 38277741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.